Pharmaceutical Formulation for Premature Ejaculation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for premature ejaculation, such as psychological therapies, topical anesthetics, and devices, have significant drawbacks including limited effectiveness, side effects, and inconvenience, while systemic medications may not work for all patients and have adverse interactions.
Innovation Solution
A pharmaceutical formulation containing escitalopram, curcumin, Rhizoma Corydalis extract, and optional piperine or turmeric oil, administered orally, which increases pre-ejaculation time with lower side effects and improved sexual pleasure, also treating depression and erectile dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychological therapies are used to treat premature ejaculation, then some patients benefit, but they require specialized therapists who may not be available to all patients and cannot alleviate premature ejaculation resulting from non-psychological causes
Solution Approach 1:
The patent replaces psychological therapies with a pharmaceutical composition containing specific compounds (e.g., dapoxetine, tramadol, or combinations with antidepressants) that directly address the physiological mechanisms of premature ejaculation, eliminating the need for specialized therapists and making treatment universally accessible
2Duration of action of moving object
If topical anesthetics are used to delay ejaculation, then pre-ejaculation time increases, but sexual pleasure is diminished and partners may experience decreased sensitivity
Solution Approach 1:
The patent uses an intermediary pharmaceutical composition that selectively targets serotonin and norepinephrine reuptake mechanisms in the central nervous system, rather than directly numbing peripheral tissues. This mediator approach delays ejaculation while preserving sexual pleasure and avoiding transfer to partners
Solution Approach 2:
The patent changes the mechanism of action from peripheral neural blocking (topical anesthetics) to central neurotransmitter modulation (SSRIs/SNRIs), fundamentally altering how ejaculation is controlled to maintain pleasure while extending duration
3Duration of action of moving object
If devices are used to treat premature ejaculation, then ejaculation timing is controlled, but they are awkward, inconvenient, embarrassing, and can cause irritation
Solution Approach 1:
The patent replaces mechanical devices with a oral pharmaceutical composition that works systemically through neurotransmitter modulation, eliminating the need for condoms, jellies, or other conspicuous devices, thereby improving convenience and eliminating embarrassment
Solution Approach 2:
The patent introduces a chemical intermediary (pharmaceutical composition) that mediates ejaculation timing control internally, replacing external mechanical devices with an internal biochemical mechanism that is non-consumptive and non-conspicuous
4Reliability
If systemic administration of fluoxetine, sertraline, Paroxetine, Dapoxetine and tramadol is used, then premature ejaculation is treated, but side effects can halt treatment or impair patient compliance
Solution Approach 1:
The patent merges multiple mechanisms of action by combining SSRIs/SNRIs with topical anesthetics or other adjunctive agents in a unified composition, allowing synergistic effects that enhance effectiveness while managing side effects through optimized dosing and combination therapy
Solution Approach 2:
The patent introduces dynamic dosing strategies and flexible treatment protocols that can be adjusted based on patient response and tolerability, allowing the treatment to adapt to individual needs and maintain compliance despite potential side effects
5Duration of action of moving object
If higher dosages of antidepressants are used to delay ejaculation, then pre-ejaculation time increases, but side effects increase and compliance decreases
Solution Approach 1:
The patent optimizes the dosage parameters of antidepressants and other components in the formulation to achieve the minimum effective concentration for delaying ejaculation while staying below thresholds that cause significant side effects, creating an optimal balance point
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining multiple agents (SSRIs, SNRIs, topical anesthetics, and other compounds) that work synergistically, allowing lower individual doses of each component to achieve the desired effect, thereby reducing overall side effect burden
Data Source
AI summary
Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.